Insider buying last 90 days
No open-market insider purchases were filed for NUVB in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every NUVB insider filing, plotted on the chart in Gekko.Open NUVB in Gekko
NYSE: NUVB
Nuvation Bio (NUVB) Stock Analysis & Forecast
Oct 12 close
$4.90−0.10 (−2.0%)
Gekko Brief
AI summaryOct 12 closeNuvation Bio trades at $4.90, down 2%, sitting between its 50-day average of $6.15 and 200-day average of $5.65. The stock has fallen 19.3% over the past month and 16.9% over three months, though it remains up 4.3% over six months and 30.7% over the past year. The GekkoIndex reads 71.3, placing NUVB in the Buying zone, while the gap to Gekko Fair Value of $7.16 stands at -31.6%, with price currently below that level.
The next earnings report is due 2 November 2026, 21 days away, falling inside a typical 20-trading-day holding window; the prior release on 6 August 2026 showed an EPS of -0.15 against a -0.14 estimate, with a 3.6% reaction. Smart-money data shows no insider, Congress or unusual options activity in their respective windows, though two billionaire holders are recorded. Analyst coverage remains uniformly positive, with all 9 firms rating the stock a buy and a consensus target of $13, implying 165.3% upside per that consensus. Seasonality over five years shows the next 20 trading days from this point averaging a 7.4% move, rising in 3 of those years. Worth noting is the proximity of the earnings date to the usual holding period, alongside the historical average reaction of 8.6% seen around past reports.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Nuvation Bio price vs fair value
Close $4.90200-day averageGekko Fair Value $7.16
Nuvation Bio quick facts
- Market cap
- $1.70B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$0.44
- Revenue, TTM
- $169.9M
- Profit margin
- -88.2%
- Dividend yield
- —
- Beta
- 1.62
- Volume
- 3.18M avg 5.46M
- 1-year return
- +30.7%
- Typical daily move
- ±5.3%
- Typical 20-day move
- ±12.3%
- 50-day average
- $6.15
- 200-day average
- $5.65
- Next earnings
- Nov 2
- Shares outstanding
- 350.1M
Nuvation Bio swing-trade checklist
Nuvation Bio scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $4.90 sits between the 50-day ($6.15) and 200-day ($5.65) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
71.3, Buying
Reading 71.3 is in the Buying zone.
See the GekkoIndex - Fair valuesupportive
31.6% below
Price is 31.6% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 21 days
Reports on Nov 2, 2026, 21 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+7.4% on average
From this point in the calendar, the next 20 trading days averaged +7.4% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Nuvation Bio stock chart and price history
Nuvation Bio closed at $4.90 on Oct 12, 2026, +30.7% over the past year, inside a 52-week range of $3.36 to $9.75.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −19.3%
- 3 months
- −16.9%
- 6 months
- +4.3%
- 1 year
- +30.7%
The full NUVB chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open NUVB in Gekko
Follow Nuvation Bio through every session
Put NUVB on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track NUVB in GekkoFree for 7 days. No credit card required.
About Nuvation Bio
Nuvation Bio works on experimental medicines for cancer, testing them in clinical studies rather than selling approved products. Its most advanced candidate, NUV-422, is a small molecule built to block CDK2, CDK4 and CDK6, enzymes involved in cell division that are often implicated in tumor growth.
Beyond that lead program, the company is developing several other compounds aimed at different cancer-related targets. NUV-868 is an oral BET inhibitor meant to affect proteins tied to tumor growth and cell differentiation, while NUV-569 targets Wee1 kinase to interfere with how cancer cells repair DNA damage. NUV-1182 works against adenosine receptors, and a separate drug-drug conjugate platform is being built to pair a PARP inhibitor with existing cancer treatments, with a focus on ER-positive breast and ovarian cancers.
The company traces back to 2018, when it was founded under the name RePharmation Inc., adopting the Nuvation Bio name in April 2019. It is headquartered in New York, New York, and its shares trade on the NYSE under the ticker NUVB.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- nuvationbio.com
Nuvation Bio GekkoIndex: the smart money zone
Nuvation Bio’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 71.3, in the Buying zone, down 6.5 points over five sessions.
71.3Buying
Down 6.5 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying (current zone) | 37 | +2.7% | +1.7% | ||
| Accumulation | 195 | +1.2% | +3.3% | ||
| Neutral | 407 | +1.9% | +5.8% | ||
| Distribution | 42 | −0.1% | +23.4% | ||
| Selling | 1 | Too few readings yet | |||
Average NUVB share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +3.1% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
See every daily GekkoIndex reading plotted over the NUVB price, zone by zone.Track NUVB in Gekko
Is Nuvation Bio stock overvalued? Gekko Fair Value
Nuvation Bio trades 31.6% below Gekko Fair Value of $7.16, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Nuvation Bio shares are worth, recalculated every trading day.
$7.16
Gekko Fair Value, Oct 10, 2026
31.6% Undervalued
At the end of Aug 2026 the price was 15.2% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open NUVB in Gekko
Nuvation Bio insider and Congress trading
No open-market insider purchases were filed for Nuvation Bio, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in NUVB were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for NUVB, plotted on the chart in Gekko.Open NUVB in Gekko
Buybacks
Nuvation Bio has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $17.14M
- As a share of market cap
- 1.01%
From company filings.
Hedge funds and billionaires quarter ended Mar 31
2of the funds Gekko tracks hold NUVB.
0added1opened1trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Nuvation Bio earnings: next date and track record
Nuvation Bio reports on Nov 2, 2026 (21 days away), and beat the EPS estimate in 2 of its last 8 reports.
Next earnings report
Nov 2, 2026
21 days away
- EPS estimate
- −$0.12
- Revenue estimate
- $35.07M
2 of 8reports beat the EPS estimate
±8.6%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 6, 2026 AI summary
- What they said
- NUVB reported Q2 2026 net revenue of $23.2 million, up 25% QoQ, in line with analyst estimates. IBTROZI captured #1 market position in ROS1 TKI new patient starts, with 160 new patients initiated in Q2. First-line starts reached 85% of total, growing ~30% sequentially. Clinical data shows 90% ORR and 50-month median PFS/DOR in TKI-naive patients, supporting chronic disease-like launch dynamics.
- Guidance
- Management expects first-line patients to become the primary long-term growth driver given longer treatment duration. Growing prevalent patient pool and low discontinuation rates support a chronic disease-like revenue trajectory, though no specific numerical guidance was provided in this excerpt.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | −$0.15 est −$0.14 | $31.69M est $27.03M | +3.6% |
| May 4, 2026 | $0.01 est −$0.03 | $83.23M est $66.22M | +7.6% |
| Mar 2, 2026 | −$0.11 est −$0.11 | $41.87M est $37.81M | −26.2% |
| Nov 3, 2025 | −$0.16 est −$0.17 | $13.12M est $36.82M | −7.5% |
| Aug 7, 2025 | −$0.17 est −$0.17 | $4.83M est $3.62M | −2.1% |
| May 7, 2025 | −$0.16 est −$0.16 | $3.08M est $357K | +0.5% |
| Mar 6, 2025 | −$0.15 est −$0.14 | $5.71M est $833K | +8.0% |
| Nov 6, 2024 | −$0.15 est −$0.13 | $727K | +12.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Nuvation Bio stock forecast and analyst price targets
Analysts’ average 12-month price target for Nuvation Bio is $13.00, +165.3% from the last close, from 9 firms rating the stock in the last 90 days.
$13.00consensus 12-month target, +165.3% from the last close
Now $4.90Avg $13.00
Low $11High $21
Each firm’s latest rating in the last 90 days: 9 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 8 | RBC Capital | $20 | +308.2% |
| Sep 30 | Citi | $12 | +144.9% |
| Sep 15 | Wedbush | $11 | +124.5% |
| Sep 15 | J.P. Morgan | — | — |
| Sep 15 | Truist Financial | — | — |
+1.7%average 20-day move after past Buying readings
+7.4%average move over the next 20 trading days in the last 5 years
±5.3%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Nuvation Bio seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Nuvation Bio averaged +7.4% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.6% | 2 of 5 |
| Next 10 trading days | +5.6% | 3 of 5 |
| Next 15 trading days | +3.1% | 2 of 5 |
| Next 20 trading days | +7.4% | 3 of 5 |
| Next 30 trading days | +17.7% | 4 of 5 |
For scale, NUVB’s typical 20-trading-day move in either direction is about 12.3%.
Nuvation Bio market cap and key statistics
Nuvation Bio’s market cap is $1.70B and revenue of $169.9M over the last twelve months.
Valuation
- Market cap
- $1.70B
- EPS, TTM
- −$0.44
- Gekko Fair Value
- $7.16
Trading
- Volume
- 3.18M
- Avg volume, 20 days
- 5.46M
- 52-week high
- $9.75
- 52-week low
- $3.36
- Shares outstanding
- 350.1M
Financials
- Revenue, TTM
- $169.9M
- Profit margin
- -88.2%
- Return on equity
- -47.8%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.62
- Typical daily move
- ±5.3%
- Typical 20-day move
- ±12.3%
Nuvation Bio peers
Nuvation Bio’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Nuvation Bio stock FAQ
What is Nuvation Bio’s market cap?
Nuvation Bio’s market cap is $1.70B at the Oct 12, 2026 close of $4.90, with 350.1M shares outstanding.
What is the Nuvation Bio stock forecast?
The consensus analyst 12-month price target for Nuvation Bio is $13.00, +165.3% from the last close. Of the 9 firms that rated the stock in the last 90 days, 9 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Nuvation Bio stock overvalued or undervalued?
On Gekko’s estimate Nuvation Bio is undervalued: the Oct 12, 2026 close of $4.90 is 31.6% below Gekko Fair Value of $7.16. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Nuvation Bio report earnings next?
Nuvation Bio is expected to report on Nov 2, 2026 (21 days away). Analysts expect earnings of −$0.12 per share on revenue of $35.07M. Nuvation Bio beat the earnings estimate in 2 of its last 8 reports, moving 8.6% on average across the report.
What is Nuvation Bio’s 52-week high and low?
Nuvation Bio’s 52-week high is $9.75 and its 52-week low is $3.36; it closed at $4.90 on Oct 12, 2026, +30.7% over the past year. Over the last five years the shares peaked at $10.45 on Dec 7, 2021.
Is Nuvation Bio stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and seasonality), 1 as mixed (trend) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Nuvation Bio the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.